

## HEDIS® Tip Sheet\*

# Colorectal Cancer Screening (COL)



The National Committee for Quality Assurance (NCQA) developed Healthcare Effectiveness Data and Information Set (HEDIS) measures as a tool for performance improvement. Blue Cross and Blue Shield of Texas collects HEDIS data from providers to measure and improve the quality of care our members receive. The NCQA recommends tracking the HEDIS COL measure.

### Why Is the HEDIS COL Measure Important?<sup>1</sup>

More than one-third of adults 50 to 75 years of age do not get recommended colorectal screenings. Early screening before symptoms present themselves can catch disease when treatment is most effective. The five-year survival rate for treatment of the earliest stage of colorectal cancer is about 90 percent.

### COL Measure Description

The measure focuses on members 50 to 75 years of age who had appropriate colorectal cancer screening with any of the following tests:<sup>2</sup>

- Fecal occult blood test (FOBT)<sup>3</sup> in the past year
- Stool DNA (FIT-DNA) test in past three years
- Flexible sigmoidoscopy in past five years
- Computed Tomography (CT) colonography in past five years
- Colonoscopy in past 10 years

### Medical Record Documentation and Best Practices

- Document the date the colorectal cancer screening was performed or the pathology report indicating the type and date of screening
- Discuss with our members the importance of returning for follow-up visits
- Reach out to members who cancel appointments and assist them with rescheduling as soon as possible

### Coding Instructions

Use CPT®, HCPCS and ICD-10 to close care gaps

#### FOBT Lab Test

CPT: 82270, 82274

HCPCS: G0328

#### FIT-DNA Lab Test

CPT: 81528

HCPCS: G0464

#### Flexible Sigmoidoscopy

CPT: 45330-50

HCPCS: G0104

#### CT Colonography

CPT: 74261-3

#### Colonoscopy

CPT: 44388-45398

HCPCS: G0105 and G0121

CPT copyright 2020 American Medical Association (AMA). All rights reserved. CPT is a registered trademark of the AMA.

The above material is for informational purposes only and is not a substitute for the independent medical judgment of a physician or other health care provider. Physicians and other health care providers are encouraged to use their own medical judgment based upon all available information and the condition of the patient in determining the appropriate course of treatment. The fact that a service or treatment is described in this material is not a guarantee that the service or treatment is a covered benefit and members should refer to their certificate of coverage for more details, including benefits, limitations and exclusions. Regardless of benefits, the final decision about any service or treatment is between the member and their health care provider.

\* Measurement Year (MY) 2020 and MY 2021

1 NCQA HEDIS MY 2020 & MY 2021, HEDIS measure for Colorectal Cancer Screening, accessed 7/14/2020; <https://www.ncqa.org/hedis/measures/colorectal-cancer-screening/>

2 NCQA HEDIS MY 2020 & MY 2021 Technical specifications for health plans, volume 2, Washington DC, 2020

3 NCQA HEDIS MY 2020 & MY 2021 Technical specifications; Guaiac Fecal Occult Blood Testing (gFOBT) requires three or more returned samples to meet this measure; Fecal Immunochemical Testing (FIT) requires one returned sample to meet this measure

HEDIS is a registered trademark of the NCQA

Blue Cross®, Blue Shield® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans.

Blue Cross and Blue Shield of Texas, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association  
753747.0720